You say that like no one should still be holding ABMD. This is a really great company with a recurring-replacement-revenue component that’s somewhat rare in the biomed space, and has done really well. And they’ve barely even tapped the global market. Not to mention the fact that they’re literally improving (and saving!) the lives of the patients whose doctors use Abiomed products.
Anyone who bought anywhere below the $300 mark has no good reason to be selling, IMO. ABMD is still one of my largest and highest-conviction holdings.